Clinical nuclear medicine
Heterogeneous Response After [ 177 Lu]Lu-FAPI-2286 Combination Therapy in Metastatic Breast Cancer.
Ghasemali Divband, Masoume Chehrara, Nastaran Khodakarim, Nahid Nafissi, Leila Hassanzadeh, Hamidreza Amini
Published: 202610.1097/RLU.0000000000006242
Abstract
A 37-year-old woman with metastatic invasive ductal carcinoma, resistant to anti-HER 2 therapy, underwent [ 177 Lu]Lu-FAPI-2286 radionuclide therapy combined with antibody-drug conjugate chemotherapy. Baseline [ 68 Ga]Ga-FAPI-2286 PET/CT confirmed ex…
Preview only. Read the full abstract at the source